CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-14 | Kaye Edward M. MD Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +10,880 | 10,880 | ||
| 2025-05-14 | Landry Robert E Director | Grant or award | +7,333 | 7,333 | ||
| 2025-05-14 | Landry Robert E Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +10,880 | 10,880 | ||
| 2025-05-14 | WIERENGA WENDALL Director | Grant or award | +7,333 | 32,181 | ||
| 2025-05-14 | WIERENGA WENDALL Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +10,880 | 10,880 | ||
| 2025-05-14 | Wysenski Nancy Director | Grant or award | +7,333 | 30,610 | ||
| 2025-05-14 | Wysenski Nancy Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +10,880 | 10,880 | ||
| 2025-05-06 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 142,255 |
| 2025-05-06 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $35.01 | $70K | 140,255 |
| 2025-05-06 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 23,105 | ||
| 2025-05-05 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −4,002 | $36.68 | $147K | 60,687 |
| 2025-04-29 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $40.96 | $205K | 417,629 |
| 2025-04-22 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 142,255 |
| 2025-04-22 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $38.11 | $76K | 140,255 |
| 2025-04-22 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 25,105 | ||
| 2025-04-21 | WIERENGA WENDALL Director | Option exercise 10b5-1 | +20,000 | $6.21 | $124K | 44,848 |
| 2025-04-21 | WIERENGA WENDALL Director | Sale 10b5-1 | −20,000 | $38.46 | $769K | 24,848 |
| 2025-04-21 | WIERENGA WENDALL Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 0 | ||
| 2025-04-15 | HENDERSON JOHN T Director | Option exercise 10b5-1 | +20,000 | $6.21 | $124K | 69,538 |
| 2025-04-15 | HENDERSON JOHN T Director | Sale 10b5-1 | −3,190 | $38.66 | $123K | 66,348 |
Page 20 of 22 · 429 trades